Fabrice Egros, Ph.D. has served as a member of our board of directors since September 2013. Since April 2020, Dr. Egros has served as President, Growth Markets of Lupin Limited, an Indian publicly traded pharmaceutical company, where he previously served since October 2015 as President, Asia Pacific and Japan. From November 2012 to September 2015, Dr. Egros served as the Deputy Chief Executive Officer/Chief Operating Officer of NovaMedica LLC, a privately held pharmaceutical company, and was its Chief Operating Officer and a member of its board of directors from July 2012 to September 2015. From February 2011 to July 2012, Dr. Egros served as the Chief Operating Officer of Xanodyne Pharmaceuticals, Inc., a privately held pharmaceutical company. From September 2009 to February 2011, he served as the Senior Vice President, Corporate Business Development and Strategy of UCB, S.A., a publicly traded biopharmaceutical company. Prior to that, Dr. Egros served as the President of UCB, Inc. and of UCB Japan Co. Ltd., each a subsidiary of UCB, S.A. Prior to joining UCB, Dr. Egros held various management and executive positions at Parke-Davis, Warner Lambert Company, a privately held pharmaceutical company, and Sanofi, formerly known as Sanofi-Aventis, a publicly traded pharmaceutical company. Dr. Egros received a B.S. in Pharmacokinetics and Metabolism and a Pharm.D. and Ph.D. in Pharmaceutical Sciences from Chatenay Malabry University, and has participated in the Advanced Management Program at Harvard University.
How do I contact Fabrice Egros?
Has Fabrice Egros been buying or selling shares of Syndax Pharmaceuticals?
Fabrice Egros has not been actively trading shares of Syndax Pharmaceuticals in the last ninety days. Most recently, Fabrice Egros sold 14,030 shares of the business's stock in a transaction on Thursday, November 18th. The shares were sold at an average price of $18.03, for a transaction totalling $252,960.90. Learn More on Fabrice Egros' trading history.
Who are Syndax Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Syndax Pharmaceuticals?
In the last year, Syndax Pharmaceuticals insiders bought shares 1 times. They purchased a total of 1,250 shares worth more than $25,037.50. The most recent insider tranaction occured on June, 14th when CFO Keith A Goldan bought 1,250 shares worth more than $25,037.50. Insiders at Syndax Pharmaceuticals own 4.1% of the company.
Learn More about insider trades at Syndax Pharmaceuticals. Information on this page was last updated on 6/14/2024.
